ERBB2 and endometrial cancer: Similarly, phase 2 data demonstrate a 9-month progression free survival benefit with addition of trastuzumab (Anti-HER2/neu monoclonal antibody) to standard of care chemotherapy in patients with endometrial cancers that overexpress HER2/neu [15].